GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (FRA:0CB) » Definitions » Net Income
中文

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Net Income

: €-4.85 Mil (TTM As of Oct. 2023)
View and export this data going back to 2021. Start your Free Trial

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Oxford Cannabinoid Technologies Holdings's Net Income for the six months ended in Oct. 2023 was €-2.31 Mil. Its Net Income for the trailing twelve months (TTM) ended in Oct. 2023 was €-4.85 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Oxford Cannabinoid Technologies Holdings's Earnings per Share (Diluted) for the six months ended in Oct. 2023 was €-0.00.


Oxford Cannabinoid Technologies Holdings Net Income Historical Data

The historical data trend for Oxford Cannabinoid Technologies Holdings's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Cannabinoid Technologies Holdings Annual Data
Trend May18 May19 May20 May21 Apr23
Net Income
- -3.01 -2.40 -3.74 -6.75

Oxford Cannabinoid Technologies Holdings Semi-Annual Data
May19 Nov19 May20 Nov20 May21 Nov21 Oct22 Apr23 Oct23
Net Income Get a 7-Day Free Trial Premium Member Only -2.83 -2.40 -4.27 -2.54 -2.31

Oxford Cannabinoid Technologies Holdings Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Oxford Cannabinoid Technologies Holdings's Net Income for the fiscal year that ended in Apr. 2023 is calculated as

Net Income(A: Apr. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-7.989+1.237+0+0
=-6.75

Oxford Cannabinoid Technologies Holdings's Net Income for the quarter that ended in Oct. 2023 is calculated as

Net Income(Q: Oct. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2.751+0.444+0+0
=-2.31

Net Income for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-4.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford Cannabinoid Technologies Holdings  (FRA:0CB) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Oxford Cannabinoid Technologies Holdings's Earnings per Share (Diluted) (EPS) for the quarter that ended in Oct. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Oxford Cannabinoid Technologies Holdings Net Income Related Terms

Thank you for viewing the detailed overview of Oxford Cannabinoid Technologies Holdings's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Cannabinoid Technologies Holdings (FRA:0CB) Business Description

Traded in Other Exchanges
Address
267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT
Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Headlines

No Headlines